Objective. The aims of this study were to compare the quality of life (QOL) of women with different cancer sites; to identify predictors of QOL; and to examine the agreement between patient self-reported QOL and QOL ratings provided by clinicians and significant others.
Treatment options for gynecologic cancer include surgical interventions, chemotherapy, irradiation, and/or endocrine therapy. Most often patients are confronted with radical pelvic surgery and postoperative chemotherapy or concomitant radiotherapy. Oncological therapies have a profound impact on the quality of life (QOL) of cancer patients resulting in long-term behavioral disruptions and emotional distress [1, 2] . Significant effects of irradiation and chemotherapy on QOL have been reported in several studies [3] [4] [5] . Approximately one-third of women with breast cancer experience a psychological burden, including depressive mood [6] . Similarly, patients with gynecologic cancer reported severe emotional distress, anxiety, physical impairments, diminished sexual response, and relationship concerns at the time they are diagnosed and during and after treatment [7] [8] [9] .
In managing cancer, reducing mortality and morbidity are still the most important factors in clinical research. However, more recently QOL issues such as reducing side effects, symptom relief, and patient satisfaction have become relevant parameters in the evaluation of medical interventions. Li et al. [10, 11] investigated the long-term effects of QOL of 62 females with endometrial cancer and 46 females with cervical cancer matched with a sample of healthy women. In the endometrial cancer group, QOL was lower compared to the healthy control group, whereas the QOL of cervical cancer survivors was not different from that of healthy women. Carlsson et al. [12] found that patients previously treated with chemotherapy had poorer long-term QOL outcomes in the areas of role functioning and cognitive functioning compared to patients not treated with chemotherapy. Patients with advanced disease who received chemotherapy for at least 1 year showed a significant deterioration in QOL [13] . In contrast, Carter et al. [14] found QOL improvements in patients with ovarian cancer receiving second-or third-line chemotherapy. There was a sustained improvement in emotional and global health status and pain control even in women receiving more than six cycles. Patients who were able to attain a complete clinical response achieved higher scores in the subscales of social and emotional well-being, relationship with their doctor, and overall QOL. The physical well-being of patients with stable or progressive disease was not significantly different. In this study, the prescription of prolonged cytotoxic chemotherapy did not result in an overall deterioration of QOL.
The findings of previous QOL research in gynecologic oncology have been inconsistent. The latest information regarding the QOL experience of patients undergoing gynecological cancer treatment have been summarized in a recent review [15] . There is still a lack of well-designed studies evaluating QOL in cancer patients. Moreover, there is little information about the QOL of women who have completed treatment over an extended period of time. Given the varying survival benefits of gynecologic and breast cancer patients, it is particularly important to address the long-term impact of the disease and treatment on QOL.
The purpose of this prospective, longitudinal study was to compare various aspects of QOL of cancer patients with different cancer sites and stages of disease; to determine predictors for patients QOL; and to examine the agreement between the QOL rated by patients and the QOL rated by clinicians and significant others. The emphasis of the study was to gain a better understanding of the effects of cancer treatment during the course of disease from the perspective of the patients.
METHODS
This study was initiated in the Department of Obstetrics and Gynecology at the University Hospital in Graz and implemented in the gynecology departments of four regional hospitals in Styria, a southern county in Austria. Patients were eligible for the study if they were diagnosed with breast, cervical, ovarian, or endometrial cancer. All cancer stages were included. In each participating center, a specific member of the clinical staff (a physician or a nurse) monitored the QOL assessments. At study entry a standardized interview was conducted including five items related to sociodemographic characteristics (age, marital status, level of education, employment status, family support) and one item regarding their health condition before diagnosis (comorbidity). Data were collected using the following standardized instruments.
EORTC QLQ-C30. This 30-item cancer-specific questionnaire comprises five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, pain, nausea and vomiting), and six single items assessing additional symptoms commonly reported by cancer patients. It also includes two questions on patients' overall QOL and overall health condition, providing a global QOL score. The EORTC QLQ-C30 is a psychometrically robust instrument which was designed to be applicable to a broad range of cancer patients. All scales and single items have satisfactory levels of reliability and validity and are highly consistent across different cultural groups [16] . The EORTC QLQ-C30 was scored using the algorithm provided by the EORTC [17] . All scores obtained from subscales and single items range from 0 to 100. For the functional and global QOL scales a higher score indicates a better level of functioning. In the present study, the functional scales and the global QOL scale were used.
Quality of life index (QL-I).
The QL-I is a short measure of QOL which can be rated by both clinicians and patients. The scale measures five specific aspects of QOL: activity, daily living, health, support, and outlook, with a choice of three possible answers (0 -2). Scores range from 0 to 10 with higher scores reflecting a better QOL. The instrument has been tested for reliability in various clinical settings. Good correlations have been found between assessments made by clinicians and patients. High interrater reliability has also been reported [18, 19] . In this study the QL-I was rated by patients, by different health professionals, and by a family member or a relative.
Karnofsky performance status scale (KPS). The KPS scale is a widely used clinician-rated instrument to measure the extent to which patients' health states restrict their physical performance [20] . It is a simple scale with 11 components describing global functioning in terms of mobility and ability to maintain employment, live at home, and care for oneself. Patients are assigned to categories by clinicians using scores from 0 (worst physical condition) to 100 (best physical condition).
In this study, timing of the QOL assessments was related to clinical events experienced by patients at the following six points in time (t): 1 day before initial treatment (t1); 10 -15 days after initial treatment (t2); the day of the fourth cycle of chemotherapy (t3 only for patients who received chemotherapy); at the first clinical follow-up visit (t4); at the 6-month follow-up visit (t5); at the 1-year follow-up visit (t6). At every time point, patients' QOL was also assessed by a physician and by an oncology nurse using the QL-I. During active treatment (t1-t3) a relative or a significant other of the patient's choice and a clinical psychologist also rated the patient's QOL. In addition, the physician rated the performance status using the KPS scale each time after seeing the patient (t1-t6). Disease-and treatment-related data were retrieved from patients' medical records. The severity of surgery was rated by gynecologic surgeons on a case-by-case basis. For patients with gynecologic malignancies, pelvic surgery was rated as severe if lymphadenectomy, omentectomy, or bowel resection was performed. Mastectomy with axillary dissection for breast cancer patients was also rated as severe. All other surgical interventions were rated as moderate.
Statistics. Descriptive statistics (frequencies, means, and standard deviations) were applied for summarizing the clinical, sociodemographic, and QOL data. Differences in frequency distributions for medical and sociodemographic variables were tested by means of 2 and one-way analyses of variance (ANOVA). Data were also analyzed in terms of missing data and patient response. The response rate was defined as the number of completed questionnaires received in proportion to those expected. The expected number of forms is the total number that should have been completed by each patient according to the study protocol. Deceased patients were not considered for the response rate. MANOVAs were conducted to compare the various QOL outcomes between the subgroups. Differences between pre-and posttreatment were analyzed using MANOVAs for repeated measures. Correlation coefficients were calculated to determine the strength of relationships among variables. A multiple regression analysis was performed to identify predictors of QOL. For this procedure, the global QOL score of the EORTC QLQ-C 30 was treated as the dependent variable. Sociodemographic and medical characteristics (age, family support, comorbidity, cancer stage, severity of surgery, number of treatments, KPS) were entered as explanatory factors in the model. To determine the agreement between patient self-reported QOL and observer-raters, intraclass correlation coefficients (ICCs) were calculated. Data were analyzed using the Statistical Package for Social Science [21] .
RESULTS
A total of 262 patients from four participating centers were recruited for this study. Of those, 6 patients refused participation, another 6 were not able to complete the questionnaires because of their poor health condition, and 2 could not be scheduled because of administrative problems. The remaining 248 patients completed the QOL assessments at baseline. The sample consisted of women who were treated with surgery, chemotherapy, irradiation, hormone treatment, or a combination of these. Radical surgery with pelvic and para-aortic lymphadenectomy was performed on patients with advanced stages of cervical and ovarian cancer. For patients with endometrial cancer the depth of the invasive tumor determined whether a lymphadenectomy was performed. Ovarian cancer patients with positive lymph nodes received platinum-based combinations of chemotherapy; cervical and endometrial cancer patients received chemotherapy and/or radiation. Most breast cancer patients underwent a combination of treatment, including surgical removal of the tumor, radiotherapy, chemotherapy, and/or hormone therapy.
In Table 1 the demographic characteristics of the sample are shown. The mean age was 55.6 years (range 24 to 91 years). Patients with cervical cancer were significantly younger than patients with other cancer sites (P Ͻ 0.01). About two-thirds were married or lived with a partner; 61.6% were compulsory school graduates, 35.5% were postcompulsory educated below university level. Concerning employment status, 57.3% were homemaker or retired, and 42.6% were employed before the cancer was diagnosed. The majority of the patients had supporting family members. Support was provided primarily by the spouse, by children, by their parents, or by other relatives. There were no significant differences between the groups concerning living situation, employment status, education, and family support.
The clinical characteristics of the sample are presented in Table 2 . Of the study participants, 26.2% were diagnosed with breast cancer, 31.9% with cervical cancer, 25.8% with ovarian cancer, and 16.1% with endometrial cancer. There were significantly more ovarian cancer patients (76.6%) diagnosed with advanced stages (III, IV) than breast (12.3%), cervical (20.2%), or endometrial cancer patients (20.0%). Concerning treatment, 34.3% underwent surgery, and 54.5% were additionally treated with chemotherapy, radiotherapy, or hormone therapy. Patients with ovarian or breast cancer were treated significantly more often with a combined treatment regimen compared to patients with endometrial or cervical cancer. Levels of physical performance at baseline were commonly high, with KPS scores greater than 90 indicating that they were able to carry on normal activities with only minimal symptoms of disease. A total of 33 patients (13.7%) died, of those 3 (4.6%) had breast, 16 (20.3%) had ovarian, 11 (17.2%) had cervical, and 3 (7.5%) had endometrial cancer. Twenty-two patients (8.9%) were lost at follow-up due to other unknown reasons. Figure 1 provides an overall picture of QOL (EORTC QLQ-C30 subscales) throughout the course of disease. Baseline assessments (t1) showed that patients' global QOL (mean ϭ 65.5; SD ϭ 24.5), emotional functioning (mean ϭ 65.3; SD ϭ 23.2), and role functioning (mean ϭ 81.0; SD ϭ 30.7) was more affected than physical functioning (mean ϭ 90.3; SD ϭ 19.1), social functioning (mean ϭ 82.7; SD ϭ 22.0), and cognitive functioning (mean ϭ 88.3; SD ϭ 15.5). At t2 the scores for physical functioning, role functioning, and social functioning decreased significantly. Patients' emotional functioning and global QOL improved significantly from pretreatments (t1) to posttreatment (t4, t5, t6). After 1 year patients showed a slight decrease in all QOL areas assessed. However, subscale scores at t6 were still higher compared to pretreatment scores: (global QOL mean ϭ 81.0, SD ϭ 22.7; emotional functioning mean ϭ 86.8, SD ϭ 17.6; role functioning mean ϭ 84.0, SD ϭ 25.0); physical functioning mean ϭ 91.2, SD ϭ 19.4; social functioning mean ϭ 88.0, SD ϭ 18.5; cognitive functioning mean ϭ 90.7, SD ϭ 16.9). Throughout the course of disease the global QOL and emotional functioning scores were lower compared to all other QOL functional scores. Table 3 shows the comparison of different cancer site groups concerning the various QOL dimensions measured by the EORTC QLQ-C30. Before treatment (t1) there were no statistically significant differences among patients with gynecologic cancer or breast cancer in any of the QOL areas assessed. The scores in the various subscales ranged between 57.4 and Note. CT, chemotherapy; RT, radiotherapy; HT, hormone therapy.
FIG. 1. EORTC QLQ-C30 subscales over time.
Higher scores indicate better well-being (range 0 -100). 89.9. At t2 breast cancer patients had significantly higher mean scores in physical functioning compared to women with gynecologic cancer sites and higher scores in role functioning compared to patients with cervical cancer. At t3 patients with breast cancer showed significantly lower scores in emotional functioning compared to patients with ovarian cancer. In any of the other QOL dimensions there were no significant differences between the cancer site groups during active treatment. At the first follow-up (t4), there was only one statistically significant mean difference, suggesting significantly lower scores on the role functioning scale in cervical cancer patients compared to breast and ovarian cancer patients. At t5 and t6 women with different cancer sites did not differ in any of the QOL areas assessed.
When analyzing different stages of disease, the sample was divided into patients with earlier cancer stages (I, II) and patients with advanced disease (III, IV) ( Table 4 ). Significant differences were found only at t1 and t3 in several areas of QOL. Before treatment the scores for physical functioning, role functioning, and global OL were significantly higher in stage I and II compared to stage III and IV. Surprisingly, at t3 the score for emotional functioning were significantly higher for patients with advanced disease compared to patients with earlier disease. In the follow-up period (t4-t6) there were no statistically significant differences between the two groups.
A multiple regression analysis was conducted with global QOL as the dependent variable to identify predictors of patients' QOL ( Table 5 ). Variables that are relevant for assessing patient outcomes and relevant for clinical decision-making such as age, supporting family, comorbidity, cancer stage, number of treatments, severity of surgery, and KPS were entered as explanatory factors in the regression model. The correlations of these variables ranged from 0.008 to 0.40, indicating that the variables were largely independent. The results of the regression analyses showed that only severity of surgery and the KPS were statistically significant in predicting patients' QOL after 12 months. Comorbidity, family support, number of treatments, age, and stage of disease were not significant. However, the regression model explained only 23% of the variance (P Ͻ 0.01) with severity of surgery (t ϭ 3.903, P Ͻ 0.01) and KPS (t ϭ 3.116, P ϭ Ͻ0.01) accounting for the most variance in the judgment of patients' QOL. Table 6 shows the results of QL-I rated by patients, by health professionals, and by relatives. There were no statistically significant differences between patient self-rated QOL and the ratings provided by others. During active treatment the nurse rated patients' QOL slightly higher, whereas physicians, psychologists, and significant others provided slightly lower or equal scores than the patients themselves. After completion of treatment both the physician and the nurse tended to overestimate patients' QOL. Table 7 shows the agreement between patient-rated QOL and the observer-rated QOL. Intraclass correlations were moderate to excellent, ranging from 0.36 to 0.93. During active treatment the relative ratings were in closest agreement to patient self-ratings (ICCs 0.71-0.89), followed by the nurse ratings (ICCs 0.59 -0.68). Patient-physician ICCs were 0.46 at t1, 0.36 at t2, and 0.68 at t3. After completion of treatment all ICCs were above 0.80 indicating an excellent level of agreement between patient self-reported QOL and physician-and nurse-rated QOL.
DISCUSSION
This research was set up as a longitudinal study to assess various QOL outcomes of female cancer patients. Although QOL assessments during the course of disease may be useful in predicting long-term health outcomes, the evaluation of QOL as a routine measure in clinical management of cancer still remains a challenge. Most previous research focused primarily on the active phase of treatment and on acute side effects. As in this study, changes in QOL deserve more attention over a longer period of time. The sample was drawn from four different hospital settings including women with breast, cervical, ovarian, and endometrial cancer. Concerning sociodemographic characteristics, some known heterogeneity exists within the different disease sites. For example, cervical cancer occurs more often in younger women. The age differences in the subgroups studied conform with the demographic pattern of female cancer patients, with cervical cancer patients being the youngest and endometrial cancer patients the oldest age group [22] . Concerning socioeconomic status (employment, education, living situation), the subgroups did not differ from one another. There are also some group inequalities regarding clinical characteristics, with ovarian cancer patients having more advanced disease stages compared to patients with breast, cervical, and endometrial cancer.
The results of the EORTC QLQ-C30 showed that patients had a high level of impairments in various QOL dimensions during active treatment. Global QOL, emotional functioning, and role functioning remained low throughout the course of disease up to 1 year after completion of treatment. This implies that patients' affective problems have not recovered completely, even though they had terminated their treatment. QOL of cancer patients is affected by both the diagnosis and the [23, 24] . After the completion of cancer treatment, patients are usually able to return to a level of physical functioning consistent with that of their precancer diagnosis.
Concerning the site of cancer, the analysis showed that patients had similar pretreatment conditions independent of their diagnosis. After the initial treatment patients with gynecologic cancer sites were physically more impaired compared to breast cancer patients. This might be due to the fact that abdominal surgery is perceived as more severe than breast surgery. More extensive pelvic surgery including para-aortic lymphadenectomy may have long-term effects on patients' QOL which have not yet been fully evaluated. Overall, the site of disease had a marginal impact on patients' QOL during active treatment and no impact after the treatment was completed. In contrast, the stage of disease affected several dimensions of QOL before initiation of treatment but not during the active treatment phase and in the follow-up period. Before treatment, patients with earlier cancer stages had better scores on physical functioning, role functioning, and global QOL. Surprisingly, during chemotherapy patients with higher cancer stages had better scores on emotional functioning compared to patients with earlier stage disease. In advanced disease palliative chemotherapy may eliminate symptoms and improve QOL. There is also evidence that these patients are willing to tolerate a high level of toxicity in expectation of treatment benefits in terms of prevention of disease progression [25] .
When interpreting QOL data during the course of disease, the health status of patients before treatment must be taken into account. Patients with poor health conditions and a high level of symptoms may benefit more from treatment in terms of QOL than patients in good pretreatment condition although they may experience QOL deterioration due to side effects. In this study most cancer patients were in good physical condition with KPS scores over 90 at baseline. Slevin et al. showed that the physical health status correlates well with patients' survival [19] . In this study, the KPS and the severity of surgery were identified as significant predictors for QOL after 1 year posttreatment, whereas the number of different therapies and the stage of disease were not predictive. Apparently, the treatment regimen does not have a major confounding effect on longterm QOL outcomes, although most patients underwent combined therapies. However, the regression model explained only 23% of the variance. There may be other variables, such as toxicity or symptom distress, which have not been sufficiently considered in this study.
This study also addressed the question of to what extent health professionals, as well as significant others, were able to assess accurately the QOL of patients. Overall, the level of agreement between patient self-ratings and QOL assessments provided by other raters was lower during the active phase of treatment and higher after completion of treatment. Oncologists' perceptions may not always reflect patients physical and psychosocial experience [26] . Epstein et al. reported that the level of concordance between patients' ratings and caretakers' ratings of overall health tends to diminish with decreasing health status of the patient [27] . In this study, QOL ratings provided by health professionals were less accurate during active treatment, but excellent after completion of treatment up to 1 year of follow-up. Although patients should be the primary source of information regarding their QOL, the view of health professionals may also be important. At least implicitly, QOL considerations play a role in medical decision-making in order to define the most appropriate treatment for cancer patients.
